X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

HOUSTON-The Associated General Contractors of America’s Greater Houston Chapter has bestowed its respected APEX 2000 Award on Introgen Therapeutics Inc.’s production facility and research and development laboratory.

The newly constructed, 42,000-sf project is situated along Holcombe Boulevard near the Texas Medical Center. Introgen’s state-of-the-art production facility will manufacture gene-based INGN 201 product for cancer and other diseases. The R&D lab and administrative building abut the production facility. Much of the preclinical work for these product candidates is conducted at these facilities.

Browne, Penland, McGregor & Stephens, Architects Inc. is the designer and Vaughn Construction Co., the general contractor.

The APEX Award is conferred biannually based on reviews by a panel of judges from the construction industry, primary owners and architects. Candidates come from the 24 counties surrounding Houston. The criteria for the award include quality of the management process, completion time, completion of project within budget, new technology and overall contribution to the community.

David Enloe, Introgen’s vice president of operations, says the award is recognition of the company’s “commitment to constructing expertly designed and built research and production facilities. … Introgen’s decision to locate its campus near the Texas Medical Center is strategically important and enhances our collaborations with several institutions in the center.”

Introgen’s lead product candidate, INGN 201, has been developed in collaboration with Aventis Pharma AG, and is currently in Phase III clinical trials for the treatment of head and neck cancer. INGN 201 has been used in clinical trials throughout the world, either alone or in combination with chemotherapy and radiotherapy. Phase II clinical trials for INGN 201 are being conducted in the treatment of lung cancer, and Phase I trials have been undertaken in additional cancer indications including prostate, ovarian, bladder, brain and breast cancer.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 3 free articles* across the ALM subscription network every 30 days
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?

Dig Deeper

GlobeSt

Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.